Physician profile

Michael J Driscoll

Pulmonary Disease · Cherry Hill, NJ

NPI 1497946792

$9,574.62

in general payments reported to CMS, 2019-2025

46 companies · $2,173 in 2025

The $2,173 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,976.25
Education$85.90

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $2,067.08 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Astrazeneca Pharmaceuticals LP $1,506.36 2019-2025 Fasenra, Breztri, Airsupra
Regeneron Healthcare Solutions, INC. $535.73 2019-2025 Dupixent
Jazz Pharmaceuticals INC. $507.69 2019-2025
Genzyme Corporation $461.80 2019-2025
Boehringer Ingelheim Pharmaceuticals, INC. $436.83 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Mylan Specialty L.P. $436.00 2019-2024 Yupelri
Philips North America LLC $338.27 2019-2025 (Ak6) Vest Therapy, Vest Therapy Und
Harmony Biosciences LLC $330.54 2020-2025 Wakix
Biomerieux INC $277.43 2022
Actelion Pharmaceuticals US, INC. $244.58 2019-2024 Opsumit, Uptravi
Inari Medical, INC. $234.51 2021-2024 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Novartis Pharmaceuticals Corporation $211.69 2019-2022
United Therapeutics Corporation $157.49 2019-2022
Abbott Laboratories $156.96 2019-2021
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Baxter Healthcare $147.18 2022-2025
Genentech USA, INC. $130.59 2019-2025 Xolair
Ani Pharmaceuticals, INC. $115.93 2024-2025 Purified Cortrophin Gel
Takeda Pharmaceuticals U.S.A., INC. $112.91 2022-2025 Aralast
Verona Pharma, INC. $110.28 2025 Ohtuvayre
Amgen INC. $105.59 2022-2025 Tezspire
Merck Sharp & Dohme LLC $104.16 2022-2023 Belsomra
Grifols USA, LLC $93.63 2019-2025 Prolastin-C Liquid
Axsome Therapeutics, INC. $80.30 2023-2025 Sunosi
Insmed, INC. $78.61 2019-2025 Arikayce
Avadel Cns Pharmaceuticals, LLC $69.87 2024-2025 Lumryz
Inspire Medical Systems, INC. $61.00 2024 Inspire
Lilly USA, LLC $47.52 2025 Zepbound
Allergan, INC. $40.00 2019-2020
Advanced Respiratory, INC $37.59 2019-2020
Viatris Specialty LLC $36.52 2025 Yupelri
Resmed Corp $34.80 2021-2025
3b Medical, INC. $31.07 2025 Luna
Ambu INC. $30.76 2020
Electromed, INC. $28.60 2019-2024 Smartvest
Sunovion Pharmaceuticals INC. $22.27 2019
Abbvie INC. $18.06 2025
Idorsia Pharmaceuticals US INC $17.31 2023 Quviviq
Bayer Healthcare Pharmaceuticals INC. $17.00 2024
Mallinckrodt Hospital Products INC. $16.45 2022
Azurity Pharmaceuticals, INC. $15.89 2024 Horizant
E.R. Squibb & Sons, L.L.C. $14.52 2020
Mallinckrodt Enterprises LLC $14.02 2019
Pulmonx Corporation $13.74 2023 Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter
Teva Pharmaceuticals USA, INC. $13.63 2022
Shire North American Group INC $11.86 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael J Driscoll

$9,574.62

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $2,173 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/22950/michael-j-driscoll

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.